What Is SNAP-8?
SNAP-8 (acetyl octapeptide-3) is a synthetic octapeptide designed to mimic the N-terminal sequence of SNAP-25, a key protein in the SNARE complex that governs synaptic vesicle fusion and neurotransmitter release at the neuromuscular junction. It was developed as a topical alternative to botulinum toxin for attenuating dynamic facial expression lines without injection.
Mechanism of Action
Muscle contraction at the skin surface — the physiological driver of expression lines — depends on acetylcholine being released from motor nerve terminals via SNARE-mediated vesicle fusion. The SNARE complex requires SNAP-25, synaptobrevin, and syntaxin to assemble correctly. SNAP-8 competitively occupies the SNAP-25 binding site on the SNARE complex, preventing complete assembly and reducing the efficiency of neurotransmitter vesicle docking. The result is a partial reduction in muscle contractile intensity — not complete paralysis as with botulinum toxin, but a measurable relaxation of repeated muscular expression patterns.
Clinical Research
SNAP-8 has been studied in clinical trials for periorbital and glabellar expression lines. In a double-blind placebo-controlled study, topical application of 10% SNAP-8 reduced the appearance of expression wrinkles by approximately 63% compared to placebo after 28 days of twice-daily use.
Comparison with Argireline
SNAP-8 is the 8-amino-acid extended version of Argireline (hexapeptide-3), which targets the same SNARE pathway. SNAP-8 is believed to have a more pronounced effect due to its longer interaction surface with SNARE complex proteins.
Quick Reference
Member reference tables summarize the compound's research parameters.
Research Indications
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Peptide Interactions
This member section summarizes reported compound interactions and evidence limitations.
Reported Research Time Points
This member section summarizes reported research time points.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Quality Indicators
Research Citations
- The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study
Wang, Y., Wang, M., Xiao, S., Pan, P., Li, P., Huo, J., 2013, American Journal of Clinical Dermatology - A synthetic hexapeptide (Argireline) with antiwrinkle activity
Blanes-Mira, C., Clemente, J., Jodas, G., et al., 2002, International Journal of Cosmetic Science - Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy
Errante, F., Ledwón, P., Latajka, R., et al., 2020, Molecules - Method development for acetyl octapeptide-3 analysis by liquid chromatography-tandem mass spectrometry
Ji, M., Lee, H.S., Kim, Y., et al., 2020, Journal of Analytical Science and Technology - Clinical Safety and Efficacy Evaluation of a Dissolving Microneedle Patch Having Dual Anti-Wrinkle Effects
Shin, J.Y., Han, D., Yoon, K.Y., Jeong, D.H., Park, Y.I., 2024, Annals of Dermatology - Peptides: Emerging Candidates for the Prevention and Treatment of Skin Senescence: A Review
Pintea, A., Manea, A., Pintea, C., et al., 2025, Biomolecules